Cannabidiol Add-on Therapy in Treatment-Resistant Epilepsy: Efficacy Across Multiple Convulsive and Nonconvulsive Seizures and Spasms

April 17 – 22, 2021; Virtual Meeting
Through 144 weeks of CBD add-on treatment, ≥50% reduction in seizures seen across multiple seizure types and across nearly all 24-week windows.
Format: Microsoft PowerPoint (.ppt)
File Size: 657 KB
Released: April 26, 2021

Acknowledgements

Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Greenwich Biosciences, Inc.

Related Content

From Clinical Care Options (CCO) and Anli Liu, MD, expert insight on new epilepsy data from AAN 2021: MONEAD pregnancy, cenobamate, cannabidiol, soticlestat

Anli A. Liu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: May 28, 2021 Expired: May 27, 2022

Expert commentary from CCO on key clinical information about each FDA-approved agent for treating spinal muscular atrophy (SMA)

Nancy L. Kuntz, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 23, 2020 Expired: October 22, 2021

Expert commentary on how to support, counsel, and educate families with a new diagnosis of spinal muscular atrophy (SMA), from Clinical Care Options (CCO)

Vanessa Battista, MS, RN, CPNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 5, 2020 Expired: October 4, 2021

Expert slides from Clinical Care Options on screening, diagnosis, treatment, and interdisciplinary care for spinal muscular atrophy (SMA)

Samiah Al-Zaidy, MD Vanessa Battista, MS, RN, CPNP Nancy L. Kuntz, MD Released: September 3, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue